Financials data is unavailable for this security.
View more
Year on year Maxigen Biotech Inc had relatively flat revenues (604.43m to 622.12m), though the company grew net income 18.95% from 139.40m to 165.83m. A reduction in the cost of goods sold as a percentage of sales from 38.12% to 31.83% was a component in the net income growth despite flat revenues.
| Gross margin | 68.14% |
|---|---|
| Net profit margin | 24.16% |
| Operating margin | 20.51% |
| Return on assets | 9.56% |
|---|---|
| Return on equity | 11.12% |
| Return on investment | 11.11% |
More ▼
Cash flow in TWDView more
In 2023, cash reserves at Maxigen Biotech Inc fell by 359.87m. However, the company earned 171.20m from its operations for a Cash Flow Margin of 27.52%. In addition the company used 490.25m on investing activities and also paid 41.39m in financing cash flows.
| Cash flow per share | 1.95 |
|---|---|
| Price/Cash flow per share | 21.39 |
| Book value per share | 14.94 |
|---|---|
| Tangible book value per share | 14.94 |
More ▼
Balance sheet in TWDView more
| Current ratio | 3.09 |
|---|---|
| Quick ratio | 2.80 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in TWD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 109.73% and 18.90%, respectively. The positive trend in dividend payments is noteworthy since only some companies in the Personal & Household Prods. industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | 11.13% |
| Payout ratio (TTM) | 60.44% |
| EPS growth(5 years) | 22.52 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -22.10 |
More ▼
